Event-free survival (EFS) analysis of neoadjuvant taxane/ carboplatin with or without atezolizumab followed by an adjuvant anthracycline regimen in high-risk triple negative breast cancer (TNBC): NeoTRIP Michelangelo randomized study

L Gianni; C Huang; D Egle; B Bermejo; C Zamagni; M Thill; AA Torres; G Bianchini; ES Fernandez; S Russo; EM Ciruelos; R Greil; V Semiglazov; MA Colleoni; CM Kelly; G Mariani; L Del Mastro; R Spezia; H Ali; G Viale

doi:10.1016/j.annonc.2023.10.009

Event-free survival (EFS) analysis of neoadjuvant taxane/ carboplatin with or without atezolizumab followed by an adjuvant anthracycline regimen in high-risk triple negative breast cancer (TNBC): NeoTRIP Michelangelo randomized study

L Gianni, C Huang, D Egle, B Bermejo, C Zamagni, M Thill, AA Torres, G Bianchini, ES Fernandez, S Russo, EM Ciruelos, R Greil, V Semiglazov, MA Colleoni, CM Kelly, G Mariani, L Del Mastro, R Spezia, H Ali, G Viale

Department of Internal Medicine III - Division of Hematology, Medical Oncology, Hemostaseology, Rheumatology, Infectiology and Oncologic Center

Research output: Contribution to journal › Abstract (Journal) › peer-review

10 Citations (Web of Science)

Original language	English
Pages (from-to)	S1258-S1259
Journal	ANNALS OF ONCOLOGY
Volume	34
DOIs	https://doi.org/10.1016/j.annonc.2023.10.009
Publication status	Published - 2023

Access to Document

10.1016/j.annonc.2023.10.009

Cite this

Gianni, L., Huang, C., Egle, D., Bermejo, B., Zamagni, C., Thill, M., Torres, AA., Bianchini, G., Fernandez, ES., Russo, S., Ciruelos, EM., Greil, R., Semiglazov, V., Colleoni, MA., Kelly, CM., Mariani, G., Del Mastro, L., Spezia, R., Ali, H., & Viale, G. (2023). Event-free survival (EFS) analysis of neoadjuvant taxane/ carboplatin with or without atezolizumab followed by an adjuvant anthracycline regimen in high-risk triple negative breast cancer (TNBC): NeoTRIP Michelangelo randomized study. ANNALS OF ONCOLOGY , 34, S1258-S1259. https://doi.org/10.1016/j.annonc.2023.10.009

Gianni, L ; Huang, C ; Egle, D et al. / Event-free survival (EFS) analysis of neoadjuvant taxane/ carboplatin with or without atezolizumab followed by an adjuvant anthracycline regimen in high-risk triple negative breast cancer (TNBC): NeoTRIP Michelangelo randomized study. In: ANNALS OF ONCOLOGY 2023 ; Vol. 34. pp. S1258-S1259.

@article{f1db83d6112e404299b5c2d913ddd3bc,

title = "Event-free survival (EFS) analysis of neoadjuvant taxane/ carboplatin with or without atezolizumab followed by an adjuvant anthracycline regimen in high-risk triple negative breast cancer (TNBC): NeoTRIP Michelangelo randomized study",

author = "L Gianni and C Huang and D Egle and B Bermejo and C Zamagni and M Thill and AA Torres and G Bianchini and ES Fernandez and S Russo and EM Ciruelos and R Greil and V Semiglazov and MA Colleoni and CM Kelly and G Mariani and {Del Mastro}, L and R Spezia and H Ali and G Viale",

note = "Times Cited in Web of Science Core Collection: 0 Total Times Cited: 0 Cited Reference Count: 0",

year = "2023",

doi = "10.1016/j.annonc.2023.10.009",

language = "English",

volume = "34",

pages = "S1258--S1259",

journal = "ANNALS OF ONCOLOGY ",

issn = "0923-7534",

publisher = "Elsevier ",

}

Gianni, L, Huang, C, Egle, D, Bermejo, B, Zamagni, C, Thill, M, Torres, AA, Bianchini, G, Fernandez, ES, Russo, S, Ciruelos, EM, Greil, R, Semiglazov, V, Colleoni, MA, Kelly, CM, Mariani, G, Del Mastro, L, Spezia, R, Ali, H & Viale, G 2023, 'Event-free survival (EFS) analysis of neoadjuvant taxane/ carboplatin with or without atezolizumab followed by an adjuvant anthracycline regimen in high-risk triple negative breast cancer (TNBC): NeoTRIP Michelangelo randomized study', ANNALS OF ONCOLOGY , vol. 34, pp. S1258-S1259. https://doi.org/10.1016/j.annonc.2023.10.009

Event-free survival (EFS) analysis of neoadjuvant taxane/ carboplatin with or without atezolizumab followed by an adjuvant anthracycline regimen in high-risk triple negative breast cancer (TNBC): NeoTRIP Michelangelo randomized study. / Gianni, L; Huang, C; Egle, D et al.
In: ANNALS OF ONCOLOGY , Vol. 34, 2023, p. S1258-S1259.

Research output: Contribution to journal › Abstract (Journal) › peer-review

TY - JOUR

T1 - Event-free survival (EFS) analysis of neoadjuvant taxane/ carboplatin with or without atezolizumab followed by an adjuvant anthracycline regimen in high-risk triple negative breast cancer (TNBC): NeoTRIP Michelangelo randomized study

AU - Gianni, L

AU - Huang, C

AU - Egle, D

AU - Bermejo, B

AU - Zamagni, C

AU - Thill, M

AU - Torres, AA

AU - Bianchini, G

AU - Fernandez, ES

AU - Russo, S

AU - Ciruelos, EM

AU - Greil, R

AU - Semiglazov, V

AU - Colleoni, MA

AU - Kelly, CM

AU - Mariani, G

AU - Del Mastro, L

AU - Spezia, R

AU - Ali, H

AU - Viale, G

N1 - Times Cited in Web of Science Core Collection: 0 Total Times Cited: 0 Cited Reference Count: 0

PY - 2023

Y1 - 2023

U2 - 10.1016/j.annonc.2023.10.009

DO - 10.1016/j.annonc.2023.10.009

M3 - Abstract (Journal)

SN - 0923-7534

VL - 34

SP - S1258-S1259

JO - ANNALS OF ONCOLOGY

JF - ANNALS OF ONCOLOGY

ER -

Gianni L, Huang C, Egle D, Bermejo B, Zamagni C, Thill M et al. Event-free survival (EFS) analysis of neoadjuvant taxane/ carboplatin with or without atezolizumab followed by an adjuvant anthracycline regimen in high-risk triple negative breast cancer (TNBC): NeoTRIP Michelangelo randomized study. ANNALS OF ONCOLOGY . 2023;34:S1258-S1259. doi: 10.1016/j.annonc.2023.10.009